Sign In
Buy KMDA
$7.39
-0.120 (-1.60%)
At Close: Jun 03, 2026
Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing ...
12:00am, Monday, 27'th Apr 2020FDA announces initiatives for antibody blood products for COVID-19
05:33pm, Friday, 03'rd Apr 2020
Aimed at facilitating nationwide access to antibody-rich blood products for COVID-19 patients, the FDA has instituted an emergency investigational new drug application (eIND) process for convalescent
Reviewing Kamada (NASDAQ:KMDA) and ANI Pharmaceuticals (NASDAQ:ANIP)
06:04am, Saturday, 14'th Mar 2020
Kamada (NASDAQ:KMDA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their div
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
03:34pm, Friday, 13'th Mar 2020
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
12:00am, Friday, 13'th Mar 2020The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
11:37am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
08:05pm, Wednesday, 11'th Mar 2020
Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet pati
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
12:03pm, Wednesday, 11'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu
Kamada Plans to Utilize its Hyper-Immunoglobulin (IgG) Platform Technology to Develop an Anti-Corona (COVID-19) Immunoglobulin as a Potential Therapy for Severely Ill.
Kamada Says Plans To Initiate Development Of Anti-Coronavirus Polyclonal Immunoglobulin
12:00am, Wednesday, 11'th Mar 2020Kamada Files Annual Report for the Year Ended December 31, 2019
02:30pm, Wednesday, 26'th Feb 2020
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.
Kamada (KMDA) Receives a Buy from Chardan Capital
01:30pm, Thursday, 13'th Feb 2020
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Kamada (KMDA), with a price target of $7.00. The company's shares
